xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

517

Orlandi et al.

TABLE X-28 Evidence for CRSwNP management with furosemide Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Hashemian 1664 2016 2 Triple Blinded, Placebo Controlled Trial (n = 110) CRSwNP postoperatively treated with INCS + 300 ug furosemide vs placebo spray 6 months post ESS Meltzer endoscopic grading scale, CT, SNOT-22, VAS Furosemide significantly reduces severity of nasal polyps, SNOT-22, & VAS. Furosemide does not reduce CTscores. Passali 1566 2003 2 Randomized, non-placebo controlled trial (n = 170) CRSwsNP; furosemide 200ug (n = 97), no treatment (n = 40), mometasone INCS (n = 33), treatment started 1 month Nasal endoscopy, AcRh Furosemide reduces recurrence of nasal polyps after ESS.

inflammatory cell count but does reduce edema in un-operated patients.

Furosemide reduces recurrence of nasal polyps after ESS.

Furosemide does not reduce

Bleeding, SNOT-22, histology

endoscopy, active AcRh, AcRh to

evaluate nasal

functionality.

6 years nasal

postoperatively with

200 ug furosemide for 1

month, off for 2 months for years 1 & 2 years,

then on for 1 month off

4 months for years 3, 4, & 5. Year 6 on for 1

month off for 6 months.

CRSwNP treated 7 days prior to ESS with furosemide vs oral steroids

CRSwNP underwent ESS started 1 month postoperatively with

200 ug furosemide for 1

month, off for 2 months for years 1 & 2 years,

then on for 1 month off

4 months for years 3, 4, & 5. Year 6 on for 1

month off for 6 months.

Kroflic 1666 2006 3 Prospective cohort (n = 40)

controlled trial (n = 104)

randomized,

non-placebo

Passali 1663 2000 2 Non-blinded,